ADMA Biologics Dividende
Zukünftiges Wachstum Kriterienprüfungen 0/6
ADMA Biologics does not have a record of paying a dividend.
Wichtige Informationen
n/a
Dividendenausschüttung
0.04%
Rückkaufsrendite
| Gesamte Aktionärsrendite | 0.04% |
| Zukünftige Dividendenrendite | n/a |
| Wachstum der Dividende | n/a |
| Nächster Dividendenzahlungstermin | n/a |
| Ex-Dividendendatum | n/a |
| Dividende pro Aktie | n/a |
| Ausschüttungsquote | n/a |
Aktuelle Dividendenentwicklung
Keine Aktualisierungen
Recent updates
ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues
Oct 09
ADMA Biologics: Riding High On ASCENIV's Success
Oct 02ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price
Sep 06ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality
Aug 16ADMA Biologics: A Compelling GARP Stock For Biotech Investors
Jul 27ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 24Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?
May 30ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
May 13Giving ADMA Biologics A Well-Deserved 'Booyah'
May 12ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
May 08Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Apr 03ADMA Biologics: On A Roll Entering 2024
Jan 19Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Jan 09ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Jan 09We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet
May 12ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
Aug 21ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M
Aug 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics: A Path To Profits Looks Clear
May 12ADMA: Pertinent Updates
Apr 18ADMA Biologics' 2021 Numbers Showed Continued Strong Execution
Mar 29ADMA Biologics: 2021 Was Tough
Jan 18Stabilität und Wachstum des Zahlungsverkehrs
Rufe Dividendendaten ab
Stabile Dividende: Insufficient data to determine if ADMA's dividends per share have been stable in the past.
Wachsende Dividende: Insufficient data to determine if ADMA's dividend payments have been increasing.
Dividendenrendite im Vergleich zum Markt
| ADMA Biologics Dividendenrendite im Vergleich zum Markt |
|---|
| Segment | Dividendenrendite |
|---|---|
| Unternehmen (ADMA) | n/a |
| Untere 25 % des Marktes (US) | 1.5% |
| Markt Top 25 % (US) | 4.5% |
| Branchendurchschnitt (Biotechs) | 2.2% |
| Analystenprognose (ADMA) (bis zu 3 Jahre) | n/a |
Bemerkenswerte Dividende: Unable to evaluate ADMA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Hohe Dividende: Unable to evaluate ADMA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Gewinnausschüttung an die Aktionäre
Abdeckung der Erträge: Insufficient data to calculate ADMA's payout ratio to determine if its dividend payments are covered by earnings.
Barausschüttung an die Aktionäre
Cashflow-Deckung: Unable to calculate sustainability of dividends as ADMA has not reported any payouts.